galectin therapeutics (nasdaq: galt) is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. drug candidates based on the company’s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pathologic function. we use naturally occurring carbohydrate polymers with galactose residues to create complex carbohydrates with specific molecular weights. using these unique carbohydrate-based candidate compounds that bind and inhibit galectin proteins, we are pursuing therapies for indications where galectins have a demonstrated role in the pathogenesis of a particular disease. we focus on diseases with serious, life threatening consequences to patients, and those where current treatment options are limited. our strategy is to establish clinical development approaches that add value to the company in the shortest time possible, and to seek partners as the program advances and requires much
Company profile
Ticker
GALT
Exchange
Website
CEO
Harold Shlevin
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
PRO PHARMACEUTICALS INC
SEC CIK
Corporate docs
Subsidiaries
Galectin Therapeutics Security Corp. • Galectin Sciences LLC ...
IRS number
43562325
GALT stock data
Latest filings (excl ownership)
8-K
Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update
29 Mar 24
10-K
2023 FY
Annual report
29 Mar 24
8-K
Submission of Matters to a Vote of Security Holders
11 Dec 23
8-K
Regulation FD Disclosure
7 Dec 23
8-K/A
Results of Operations and Financial Condition
13 Nov 23
8-K
Results of Operations and Financial Condition
13 Nov 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
ARS
2022 FY
Annual report to shareholders
6 Oct 23
DEFA14A
Additional proxy soliciting materials
6 Oct 23
DEF 14A
Definitive proxy
6 Oct 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 20.36 mm | 20.36 mm | 20.36 mm | 20.36 mm | 20.36 mm | 20.36 mm |
Cash burn (monthly) | (no burn) | (no burn) | 3.06 mm | 3.26 mm | 2.55 mm | 2.96 mm |
Cash used (since last report) | n/a | n/a | 21.15 mm | 22.58 mm | 17.62 mm | 20.48 mm |
Cash remaining | n/a | n/a | -791.28 k | -2.22 mm | 2.74 mm | -120.86 k |
Runway (months of cash) | n/a | n/a | -0.3 | -0.7 | 1.1 | -0.0 |
Institutional ownership, Q3 2023
14.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 60 |
Opened positions | 5 |
Closed positions | 5 |
Increased positions | 12 |
Reduced positions | 8 |
13F shares | Current |
---|---|
Total value | 16.85 bn |
Total shares | 9.06 mm |
Total puts | 0.00 |
Total calls | 15.10 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Advisor | 3.28 mm | $6.29 bn |
Vanguard | 1.94 mm | $3.73 bn |
BLK Blackrock | 725.92 k | $1.39 bn |
Geode Capital Management | 510.43 k | $980.25 mm |
Geneos Wealth Management | 417.35 k | $801.31 mm |
Atria Wealth Solutions | 259.80 k | $498.82 mm |
MS Morgan Stanley | 184.76 k | $354.74 mm |
Sontag Advisory | 183.86 k | $353.02 mm |
STT State Street | 161.44 k | $309.97 mm |
Cambridge Investment Research Advisors | 138.17 k | $265.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
24 Apr 24 | Joel Lewis | Common Stock | Buy | Acquire P | Yes | No | 3.39 | 1,000 | 3.39 k | 2,000 |
23 Apr 24 | James C Czirr | Common Stock | Sell | Dispose S | Yes | No | 3.06 | 3,677 | 11.25 k | 5,922,207 |
22 Apr 24 | Freeman Kevin D | Common Stock | Buy | Acquire P | No | No | 2.98 | 2,500 | 7.45 k | 25,969 |
22 Apr 24 | James C Czirr | Common Stock | Sell | Dispose S | Yes | No | 3.06 | 21,323 | 65.25 k | 5,925,884 |
9 Apr 24 | Freeman Kevin D | Common Stock | By will or laws of descent | Acquire W | Yes | No | 0 | 2,063 | 0.00 | 18,063 |
1 Mar 24 | Joel Lewis | Common Stock | Grant | Dispose A | No | No | 1.96 | 152,584 | 299.06 k | 897,716 |
News
HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $11 Price Target
9 Apr 24
Galectin Therapeutics Highlights Outcome Of Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study
9 Apr 24
12 Health Care Stocks Moving In Friday's Intraday Session
5 Apr 24
HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $11 Price Target
1 Apr 24